Metabolic risk factor-profile in patients on treatment with second generation antipsychotics.

The second generation antipsychotic agents, although exhibit superior safety profile, is associated with metabolic adverse effects including weight gain, diabetes mellitus and hyperlipidaemia. These adverse effects are not only the risk factors for cardiovascular disease and diabetes mellitus but may also impair patient's adherence to treatment. However, different member of second generation antipsychotics differ. in their extent of metabolic adverse effects. The aim of the study was to evaluate the association between olanzapine, risperidone or quetiapine treatment and body mass index, blood pressure, diabetes mellitus and hyperlipidaemia in patients with Schizophrenia and Bipolar Disorder. Forty-four cases of Schizophrenia and Bipolar Disorder diagnosed with DSM-IV criteria were selected according to inclusion and exclusion criteria. Body weight, body mass index and blood pressure were measured at baseline, at the end of 4th, 8th and 12th weeks of treatment. Blood samples were collected to measure blood glucose and serum lipid profile at baseline and at the end of 4th, 8th and 12th weeks in the study group receiving treatment (olanzapine 20-30 mg/day, risperidone 4-16 mg/day and quetiapine 300-800 mg/day) after overnight fasting. Therapeutic use of olanzapine and risperidone in Schizophrenia and Bipolar Disorder for a period of 4th, 8th and 12th weeks was associated with significant increase in body weight and body mass index. Quetiapine did not cause significant changes in body weight and body mass index after 4 and 8 weeks. However, after 12 weeks treatment, body mass index increased significantly. Olanzapine, risperidone and quetiapine increased the blood glucose level significantly after 8 and 12 weeks treatment. Olanzapine and risperidone elevated the serum cholesterol, triglyceride and low density lipoprotein levels significantly after 4, 8 and 12 weeks. But quetiapine showed no significant change in lipid profile. However, olanzapine and risperidone significantly increased triglyceride level after 8 and 12 weeks. Amongst three drugs, quetiapine treatment increased high density lipoprotein level. Our study revealed that quetiapine treatment is associated with less risk of dyslipidaemia.

Development and validation of a computational model of the knee joint for the evaluation of surgical treatments for osteoarthritis.

A three-dimensional (3D) knee joint computational model was developed and validated to predict knee joint contact forces and pressures for different degrees of malalignment. A 3D computational knee model was created from high-resolution radiological images to emulate passive sagittal rotation (full-extension to 65°-flexion) and weight acceptance. A cadaveric knee mounted on a six-degree-of-freedom robot was subjected to matching boundary and loading conditions. A ligament-tuning process minimised kinematic differences between the robotically loaded cadaver specimen and the finite element (FE) model. The model was validated by measured intra-articular force and pressure measurements. Percent full scale error between FE-predicted and in vitro-measured values in the medial and lateral compartments were 6.67% and 5.94%, respectively, for normalised peak pressure values, and 7.56% and 4.48%, respectively, for normalised force values. The knee model can accurately predict normalised intra-articular pressure and forces for different loading conditions and could be further developed for subject-specific surgical planning.

Administration of exogenous testosterone in the adult rat and its effects on reproductive organs, sex hormones and body-weight.

The present experiment was performed to observe the effects produced by high dose of a testosterone ester on the reproductive organ and body weight changes in the adult rat, and to correlate these effects with the serum hormone changes. The present study has used the benzoate ester of testosterone (Testosterone benzoate, TB) in the adult male rat (300-350 g). The aim was to co-relate the reproductive organ and body-weight changes with changes in the serum hormone levels following the administration of the ester. TB was injected i.p. for five (5) consecutive days at a dose of 100 mg/kg body-weight. The control rats were injected with vehicle (arachis oil) at the same dose. The rats were killed on the 6th, 12th, 18th, 24th and 36th days. Controls for only the 6th and 36th days were kept. Reproductive organ weight, body-weight and testosterone (T) levels in serum and testis together with serum FSH and serum LH levels were observed. The testes weights remained similar (p < 0.05) to those in the control rats until the 18th days and were reduced on the 36th day. The epididymis weights were not changed until the 36th days, while the androgen-dependent seminal vesicle and ventral prostate weights were increased (< 0.05) compared to those in the control rats. The body-weights remained unchanged at the 6th day but were significantly (p < 0.05) decreased on the 36th day. The serum testosterone (ST) concentrations were highly raised on the 6th day, came at the control level on the 18th day and were significantly decreased (< 0.05) on the 36th day. The testicular testosterone (TT) content remained significantly lower (p < 0.05) from the 6th to the 36th days post-injection. The serum LH and FSH levels also remained significantly lower (p < 0.05) throughout the treatment period. It appears that the elevated serum T levels exerted dual effect in the adult rats, namely, enhanced growth of the androgen-dependent organs and an inhibition over the hypothalamo-pituitary-testicular axis. Inhibition of the said axis was evident by the lower levels of the serum LH and FSH; probably due to this, the TT-content remained all through lower, and perhaps this low TT-content for the long period had led to the low testis weights (p < 0.05) on the 36th day. This experiment therefore, demonstrates the effects of exogenous androgen administration in the adult male rat physiology.